**Core tip:** It is a great challenge to define new biomarkers of hepatocellular carcinoma (HCC) risk for HCC management. This work identified five genetic markers in key pathways linked to hepatocarcinogenesis (*ERCC1* rs3212986, *GSTP1* rs1138272, *CYP17A1* rs743572, *XRCC3* rs1799794, and *ABCB1* rs112850), which could predict individual HCC susceptibility, particularly in a high-risk \[hepatitis B viral/hepatitis C viral (HCV)-infected\] Caucasian population. We also identified potential gene-gene interactions that should be included in the definition of HCC risk. These findings could contribute to improved HCC surveillance, early cancer diagnoses, and potential curative therapies. For patients with HCV, these markers could be considered selection criteria for the personalized use of recently developed, highly expensive anti-viral therapies.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a particularly high prevalence in some areas of Asia and Africa. HCC represents the second leading cause of cancer-related deaths\[[@B1]\]. Although liver cancer is less frequent in Western developed countries, recent data indicate that, due to dissemination of hepatitis B (HBV) and C (HCV) viral infections, the HCC incidence is also dramatically rising, in both the United States and Europe\[[@B1],[@B2]\].

Unlike most malignancies, the major risk factors for HCC development are well-defined. These risk factors are chronic HCV and HBV infections, liver cirrhosis, heavy alcohol intake, tobacco smoking, exposure to environmental and dietary carcinogens (*i.e*., aflatoxin B1), genetic and metabolic liver disease (*i.e*., hereditary hemochromatosis, non-alcoholic steatohepatitis), and other conditions capable of inducing liver damage\[[@B2]\]. Moreover, the prevalence of HCC increases with age and male sex\[[@B1]-[@B3]\].

In addition to environmental factors, recent insights into the biology of HCC have demonstrated that accumulations of genetic and epigenetic abnormalities can also play an essential role in liver carcinogenesis. In particular, data derived from candidate-gene investigations and, more recently, genome-wide associations studies have highlighted the possible role that genetic variants might play as significant determinants of HCC susceptibility\[[@B4]-[@B6]\]. Additionally, host genetic factors were shown to affect the clinical course of HBV or HCV infections, because they influence the individual's predisposition to disease progression and hepatocarcinogenesis\[[@B7],[@B8]\]. However, the currently available studies are highly heterogeneous in study design, sample size, ethnicity, and clinical-demographic features of the investigated population; these differences make it difficult to draw solid conclusions\[[@B4],[@B6]\]. Moreover, the majority of case-control investigations were performed with Asian populations; thus, replication studies with different ethnicities are warranted\[[@B4]-[@B8]\].

It is of great clinical interest to identify genetic traits that can modify liver carcinogenesis, because they can potentially be used to improve preventive, diagnostic, and therapeutic strategies in HCC management\[[@B3],[@B9],[@B10]\]. To date, the majority of patients with HCC are diagnosed at an advanced tumor stage, which precludes potentially curative therapies, including orthotopic liver transplantation (OLT), surgical resection, and local ablation\[[@B3],[@B9],[@B10]\]. The HCC surveillance programs that could lead to early cancer detection and effective treatment are currently based on highly heterogeneous scoring systems that require costly measures\[[@B3],[@B9],[@B10]\]. The identification of additional molecular biomarkers predictive of individual HCC susceptibility, particularly in a high-risk population (*i.e*., HBV/HCV-positive), could be important in improving current guidelines for genetics-based patient screening and preventive strategies. In some countries, including the United States and Europe, HCV-related HCC accounts for most liver cancer incidents\[[@B11]\]. Consequently, an increased understanding of the genetic contribution to the clinical course of viral infection could be essential in optimizing the use of newly developed, but highly expensive, direct acting antiviral (DAA) treatments\[[@B12],[@B13]\].

We previously reported that the low-activity alleles, *UGT1A1*\*28, *UGT1A7*\*3, *UGT1A9*\*22, and related haplotypes may play a protective role against HCC development in Caucasian populations. These alleles positively modulate the serum levels of beneficial molecules, like bilirubin\[[@B14]\]. The present study aimed to extend genetic analyses by identifying additional molecular markers that could be integrated into the HCC risk stratification algorithms used in liver cancer prevention strategies. To that end, we analyzed a set of potential candidate HCC-risk markers with low penetrance. These candidate markers were based on functionally relevant polymorphic variants in genes that encoded proteins involved in key pathways underlying carcinogenesis\[[@B6],[@B15]-[@B17]\]. The pathways we investigated were: (1) membrane transporters that play an essential role in xenobiotic defense and prevent the entry of toxic environmental compounds that might damage liver tissue; (2) DNA synthesis and repair mechanisms that modulate the cell's capacity to respond to DNA damage induced by toxic agents, and thus, these mechanisms affect the accumulation of mutations in DNA; (3) detoxification systems that facilitate the elimination of detrimental endo/exogenous compounds; and (4) systems that defend against oxidative stress and related cellular damage, which can play a crucial role in the development and progression of HCC. We designed a retrospective case-control study and enrolled a homogeneous group of patients with HCC that had received OLT and two age/sex-matched control groups (a group positive for HBV and/or HCV and a healthy population). We aimed to identify novel genetic markers that could contribute to the determination of individual HCC risk, particularly in Caucasian populations.

MATERIALS AND METHODS
=====================

Study population
----------------

We studied 192 patients with histologically confirmed HCC that had undergone OLTs between May 1991 and March 2006 at the Liver Transplantation Center of the S. Giovanni Battista Hospital (Turin, Italy). All patients were infected with HBV and/or HCV and had a cirrhotic liver. The first control group included 167 subjects with HBV and/or HCV infections, but no evidence of cancer (including HCC). These subjects were followed up for hepatitis infections between November 2009 and September 2010 at the Department of Laboratory Medicine, S. Maria degli Angeli Hospital (Pordenone, Italy). This control group was matched to the HCC group to ensure equivalent percentages of patients with HBV and/or HCV and similar distributions of gender and age (in quinquennia), when possible.

The second control group included 192 healthy subjects that were matched to patients with HCC for gender and age (in quinquennia). For this control group, individuals under 70 years of age were randomly selected from a pool of blood donors that visited the Centro di Riferimento Oncologico National Cancer Institute in Aviano, Italy. This control group also included individuals aged ≥ 70 years that were cancer-free without HBV/HCV infections. These individuals had been approached during occasional blood testing at the S. Maria degli Angeli Hospital, and they consented to provide a 5-mL blood sample for research purposes.

All cases and controls were Italian Caucasian individuals, and they all provided written informed consent for genetic analysis and for inclusion in the study. The study protocol conformed to the ethics guidelines of the 1975 Declaration of Helsinki, and it was approved by the Institutional Review Board of each participating institution (Ethics Committee of Azienda Ospedaliera Universitaria, S. Giovanni Battista, Torino).

Polymorphism selection and genetic analyses
-------------------------------------------

Genomic DNA was extracted from peripheral blood with the High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany). The samples underwent standard proteinase K digestion and successive template purification. The genomic DNA solution was stored at 4 °C. Positive and negative control samples were included in each analysis.

We considered a set of 31 molecular markers that represented functionally relevant polymorphisms (PubMed-MEDLINE search) in genes that encoded key proteins involved in hepatocarcinogenesis-related pathways. In particular, the biological processes evaluated (and related genes) were: membrane transport (*ABCB1, ABCC2*), DNA synthesis and repair mechanisms (*MTHFR, TYMS, ERCC1, ERCC2, XRCC1, XRCC3, APE1, hMLH1, hMSH2, hOOG1*), detoxifying systems (*CYP3A4, CYP3A5, CYP17A1, CYP2D6*), and oxidative stress response (*GST-M1, GST-T1, GST-P1; GSTA1, SOD2*).

All the genes, variants, and assays applied are listed in Supplementary Table 1. For pyrosequencing, we used PSQ96MA (Qiagen, Hilden, Germany). PCR amplifications were performed in an Eppendorf Mastercycler gradient, with TaqGold DNA Polymerase (AB Applied Biosystems, Foster City, CA, United States). The details of the pyrosequencing assays, primer sequences, and PCR conditions are available upon request. Pre-designed TaqMan single-nucleotide polymorphism genotyping assays were conducted with the Applera TaqMan Universal Master mix on an ABI 7900HT Real-time PCR system (AB Applied Biosystems, Foster City, CA, United States), according to the manufacturer's instructions for optimal allelic discrimination. All commercial TaqMan assays were purchased from the Applied Biosystems website ([www.appliedbiosystems.com](www.appliedbiosystems.com)). Detailed protocols for genotyping methods, based on gel electrophoresis and enzymatic digestion, are available upon request.

###### 

Distribution of hepatocellular carcinoma patients, hepatitis B/hepatitis C -positive individuals and healthy subjects according to socio-demographic and clinical characteristics *n* (%)

  **Characteristics**                                      **HCC group**   **HBV/HCV group**   **Healthy group**
  -------------------------------------------------------- --------------- ------------------- -------------------
  Sex                                                                                          
  Men                                                      166 (86.5)      141 (84.4)          166 (86.5)
  Women                                                    26 (13.5)       26 (15.6)           26 (13.5)
  Age (yr)                                                                                     
  \< 55                                                    85 (44.3)       85 (50.9)           96 (50.0)
  55-59                                                    60 (31.3)       19 (11.4)           35 (18.2)
  ≥ 60                                                     47 (24.5)       63 (37.7)           61 (31.8)
  Hepatitis infection                                                                          
  None                                                     0 (0.0)         0 (0.0)             192 (100.0)
  HBV+ and HCV-                                            74 (38.5)       74 (44.3)           0 (0.0)
  HBV- and HCV+                                            109 (56.8)      88 (52.7)           0 (0.0)
  HBV+ and HCV+                                            9 (4.7)         5 (3.0)             0 (0.0)
  Years of orthotopic liver transplantation or resection                                       
  1991-1995                                                27 (14.1)                           
  1996-2000                                                60 (31.3)                           
  2001-2006                                                102 (54.7)                          
  Number of nodes                                                                              
  1                                                        110 (57.3)                          
  ≥ 2                                                      72 (37.5)                           
  Unknown                                                  10 (5.2)                            
  Maximal dimension of nodes (cm)                                                              
  ≤ 2                                                      79 (41.2)                           
  2.1 to ≤ 3                                               67 (34.9)                           
  \> 3                                                     37 (19.3)                           
  Unknown                                                  9 (4.7)                             

HCC: Hepatocellular carcinoma; HBV: Hepatitis B viral; HCV: Hepatitis C viral.

Statistical analysis
--------------------

In this study, we assessed associations between genetic markers and the individual risk of developing HCC. In healthy controls, deviation from Hardy-Weinberg equilibrium was tested for each polymorphism with the *χ*^2^ test, and no deviation was found (*P* \< 0.05).

The odds ratio (OR) and 95%CI were estimated with unconditional logistic regression, which was controlled for matching variables. We also investigated three genetic models (dominant, recessive, and additive) for associations, and we reported the most statistically significant one, based on the Wald *χ*^2^-test. Statistical significance was set at *P* \< 0.05 (two-sided). The analyses were performed with SAS 9.2, and a statistical review of the study was performed by a biomedical statistician.

Recursive partitioning was performed to elucidate high-order relationships among genetic factors, when stratifying patients between HCC cases and HBV/HCV group. The analysis was carried out with the five genetic variants that were identified in the present study as significant predictors of HCC risk and with the previously described *UGT1A* markers (*i.e., UGT1A1*\*28, *UGT1A9*\*22, *UGT1A7*\*3)\[[@B14]\].

RESULTS
=======

Patient characteristics
-----------------------

The demographic, clinical, and serological characteristics of the 192 patients with HCC and the two control groups are reported in Table [1](#T1){ref-type="table"}. The predominant gender was male (86.5% of patients with HCC, 84.4% of patients in the HBV/HCV group, and 86.5% of healthy subjects). The median ages at the time of enrolment were 56, 54 and 55 years for the HCC, HBV/HCV, and healthy groups, respectively. The HCC cohort was clinicopathologically homogeneous; all patients fulfilled the surgical intervention criteria (*i.e*., T1/T2 primary tumor stage, evaluated with the TNM scale; well or moderately poorly differentiated grade at diagnosis; and no detectable vascular invasion).

Genetic polymorphisms and HCC risk
----------------------------------

The average genotype call rates were 0.98 (range: 0.92-1.00), 1.00 (range: 0.99-1.00), and 0.99 (range: 0.95-1.00) for the HCC, HBV/HCV, and healthy groups, respectively. All case and control samples were included in the study, because they all reached the fixed call rate threshold of 90%.

**HCC *vs* HBV/HCV group:** Considering that chronic HBV and/or HCV infections represent a major risk factor for HCC development, a case/control analysis was initially performed to compare the genotype frequency distribution between patients with HCC and individuals without HCC, but with matched HBV/HCV infections. The frequency distributions of variant genotypes were significantly different between cases and controls (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) for five polymorphisms. No Hardy-Weinberg disequilibrium among healthy controls was detected (*P* \> 0.05), which suggested that it was a representative sampling of the investigated population. The observed genotype frequency distribution in healthy controls was consistent with data published in the literature for a Caucasian population ([www.ncbi.nlm.nih.gov/snp](www.ncbi.nlm.nih.gov/snp)).

###### 

Distribution of gene polymorphisms in patients with hepatocellular carcinoma, in hepatitis B/hepatitis C -positive patients, and in healthy controls *n* (%)

  **Gene**    **SNP**     **Genotype**   **HCC group**   **HBV/HCV group**   **Healthy group**
  ----------- ----------- -------------- --------------- ------------------- -------------------
  *ERCC1*     rs3212986   GG             126 (67.7)      82 (49.1)           91 (47.4)
                          GT             44 (23.7)       78 (46.7)           81 (42.2)
                          TT             16 (8.6)        7 (4.2)             20 (10.4)
  *XRCC3*     rs1799794   AA             128 (66.7)      108 (65.1)          137 (71.7)
                          AG             52 (27.1)       55 (33.1)           49 (25.7)
                          GG             12 (6.3)        3 (1.8)             5 (2.6)
  *GST-P1*    rs1138272   CC             172 (92.5)      139 (83.2)          182 (94.8)
                          CT             13 (7.0)        27 (16.2)           10 (5.2)
                          TT             1 (0.5)         1 (0.6)             0 (0.0)
  *CYP17A1*   rs743572    TT             72 (38.1)       39 (23.4)           54 (28.4)
                          TC             84 (44.4)       88 (52.7)           91 (47.9)
                          CC             33 (17.5)       40 (24.0)           45 (23.7)
  *ABCB1*     rs1128503   CC             54 (28.1)       52 (31.1)           58 (30.2)
                          CT             92 (47.9)       93 (55.7)           95 (49.5)
                          TT             46 (24.0)       22 (13.2)           39 (20.3)

HCC: Hepatocellular carcinoma; SNP: Single-nucleotide polymorphism; HBV: Hepatitis B viral; HCV: Hepatitis C viral.

###### 

Odds ratios and corresponding 95%CI for hepatocellular carcinoma compared to hepatitis B/hepatitis C infected patients and blood donors according to genetic polymorphisms

  **Gene**    **SNP**     **Allelic change**   **HCC *vs* HBV/HCV**   **HCC *vs* Healthy**                                                                     
  ----------- ----------- -------------------- ---------------------- ---------------------- ---------------------------------------- ----- ------------------ -------------------------------------------
  *ERCC1*     rs3212986   G\>T                 Dom                    0.46 (0.30-0.71)       0.0005[b](#T3FN4){ref-type="table-fn"}   Dom   0.43 (0.28-0.65)   \< 0.0001[b](#T3FN4){ref-type="table-fn"}
  *XRCC3*     rs1799794   A\>G                 Rec                    3.70 (1.02-13.39)      0.0461[a](#T3FN3){ref-type="table-fn"}   Rec   2.44 (0.84-7.08)   0.1003
  *GST-P1*    rs1138272   C\>T                 Dom                    0.41 (0.21-0.81)       0.0097[b](#T3FN4){ref-type="table-fn"}   Add   1.58 (0.70-3.57)   0.2699
  *CYP17A1*   rs743572    T\>C                 Dom                    0.50 (0.31-0.79)       0.0032[b](#T3FN4){ref-type="table-fn"}   Add   0.73 (0.55-0.97)   0.0310[a](#T3FN3){ref-type="table-fn"}
  *ABCB1*     rs1128503   C\>T                 Rec                    2.06 (1.18-3.61)       0.0111[a](#T3FN3){ref-type="table-fn"}   Dom   1.22 (0.75-1.98)   0.4194

Estimated through logistic regression model, adjusted for sex, age and HBV and/or HCV infection;

Estimated through logistic regression model, adjusted for sex and age.

*P* \< 0.05,

*P*\< 0.01. HCC: Hepatocellular carcinoma; SNP: Single-nucleotide polymorphism; HBV: Hepatitis B viral; HCV: Hepatitis C viral.

Specifically, *ERCC1* rs3212986 (OR = 0.46, *P* = 0.0005), *GST-P1* rs1138272 (OR = 0.41, *P* = 0.0097), and *CYP17A1* rs743572 (OR = 0.50, *P* = 0.0032) markers were observed more frequently in the HBV/HCV group than in the HCC group, and they were significantly associated with reduced liver cancer risk, according to the dominant model. In contrast, the frequency of *XRCC3* rs1799794 (OR = 3.70; *P* = 0.0461) and *ABCB1* rs1128503 (OR = 2.06; *P* = 0.0111) markers were higher in the HCC group than in the HBV/HCV group, and they were associated with increased HCC risk, according to the recessive model (Table [3](#T3){ref-type="table"}).

Given the molecular and clinicopathological differences between HBV- and HCV- related hepatocarcinogenesis\[[@B18]\], a similar analysis was also carried out in subgroups, divided according to viral status (Table [4](#T4){ref-type="table"}). In all cases, the ORs calculated for the HBV- and HCV-positive subgroups were concordant with those obtained for the entire combined group. The association was significant in both sub-groups for *CYP17A1* rs743572 (OR = 0.45, *P* = 0.0315 and OR = 0.51, *P* = 0.0384 in HBV-positive and HCV-positive subgroups, respectively). In contrast, *ABCB1* rs1128503 (OR = 4.18, *P* = 0.0048, HBV-positive subgroup) and *ERCC1* rs3212986 (OR = 0.33, *P* = 0.0003, HCV-positive subgroup) showed significant associations in only one sub-group.

###### 

Odds ratios and corresponding 95%CI for hepatocellular carcinoma compared to hepatitis B/hepatitis C infected patients according to the viral status

  **Gene**    **SNP**     **Allelic change**   **Mod**   **HCC *vs* HBV/HCV**                                                                
  ----------- ----------- -------------------- --------- ---------------------- ---------------------------------------- ------------------- ----------------------------------------
  *ERCC1*     rs3212986   G\>T                 Dom       0.59 (0.30-1.15)       0.1231                                   0.33 (0.18-0.60)    0.0003[b](#T4FN3){ref-type="table-fn"}
  *XRCC3*     rs1799794   A\>G                 Rec       2.23 (0.39-12.82)      0.3695                                   6.73 (0.82-55.03)   0.0753
  *GST-P1*    rs1138272   C\>T                 Dom       0.40 (0.14-1.15)       0.0881                                   0.41 (0.16-1.02)    0.0558
  *CYP17A1*   rs743572    T\>C                 Dom       0.45 (0.22-0.93)       0.0315[a](#T4FN2){ref-type="table-fn"}   0.51 (0.27-0.97)    0.0384[a](#T4FN2){ref-type="table-fn"}
  *ABCB1*     rs1128503   C\>T                 Rec       4.18 (1.55-11.29)      0.0048[b](#T4FN3){ref-type="table-fn"}   1.49 (0.71-3.11)    0.2893

Estimated through logistic regression model, adjusted for sex, age and HBV and/or HCV infection.

*P* \< 0.05,

*P* \< 0.01. HCC: Hepatocellular carcinoma; SNP: Single-nucleotide polymorphism; HBV: Hepatitis B viral; HCV: Hepatitis C viral.

**HCC *vs* healthy group:** We also conducted a case case/control analysis of the genotype frequency distribution in patients with HCC compared to individuals without HCC or virus infections to evaluate the extent of the predictive value of the selected five markers (Table [3](#T3){ref-type="table"}). Two markers were significantly associated with HCC risk. Specifically, *ERCC1* rs3212986 (OR = 0.43, *P* \< 0.0001) and *CYP17A1* rs743572 (OR = 0.73, *P* = 0.0310) were associated with reduced HCC risk, according to the dominant and additive models, respectively.

**Classification and regression tree analysis:** The Classification and Regression Tree (CART) method allowed us to identify 6 subgroups of subjects according to genotype features, each with a different probability of HCC occurrence. Three of the terminal nodes exhibited high-probability (59%-76%), two exhibited intermediate-probability (36% and 40%), and one exhibited low-probability (6%) of developing HCC (Figure [1](#F1){ref-type="fig"}). The ORs and 95%CIs were calculated for each high/intermediate-probability group, with respect to the reference low-probability group. The group with the highest percentage of HCC cases (group 5) was associated with an approximately 13-fold higher HCC risk compared to the reference low-probability group. The first node of the tree represented the *ERCC1* rs3212986 variant, which significantly interacted with *CYP17A1* rs743572, *GST-P1* rs1138272, and the *UGT1A7*\*3 marker in the generation of the tree (Figure [1](#F1){ref-type="fig"}).

![Classification and regression tree representation of the markers combination significantly predictive of hepatocellular carcinoma risk. Fractions indicate the number of HCC cases patients *vs* number of HBV/HCV infected patients (percentage of cases in parenthesis). Black circles represent terminal nodes with high probability to develop hepatocellular carcinoma (HCC) (ratio ≥ 70%); gray circles represent terminal nodes with intermediate probability to develop HCC (30 ≤ ratio \< 70%); white circles represent terminal nodes with low probability to develop HCC (ratio \< 30%). Odds ratios (OR) and 95%CI were calculated for each group in respect to the reference group (lower HCC risk) through logistic regression model, adjusted for sex, age and viral status. ^1^Number of alleles carried by the patient. CART: Classification and regression tree; HCC: Hepatocellular carcinoma; HBV: Hepatitis B viral; HCV: Hepatitis C viral.](WJG-23-6674-g001){#F1}

DISCUSSION
==========

HCC is a global healthcare problem. It is one of the most common malignancies worldwide, with an increasing incidence in Western developed countries. It represents the second cause of death attributable to cancer\[[@B1],[@B2]\]. The genetic origin of HCC has been a focus of research in the past few years. Some studies found that genetic variants could be predictive of the clinical course of HBV or HCV and an individual's predisposition to developing liver cancer\[[@B4]-[@B8]\]. However, those studies were performed mainly in Asian populations; thus, few data are available on Caucasian populations. The ethnicity of the population being studied is a crucial factor in case-control studies, because polymorphism frequency varies greatly with geographical origin. This association could give rise to ethnicity-specific phenotypic effects\[[@B4],[@B14]\]. The present study revealed some novel genetic markers that could be used as early diagnosis indicators for liver cancer susceptibility in Caucasians. The availability of these markers could improve HCC risk stratification algorithms and surveillance programs.

The main result of this work was the identification of five polymorphisms (*ERCC1* rs3212986, *GST-P1* rs1138272, CY*P17A1* rs743572, *XRCC3* rs1799794, and *ABCB1* rs1128503) that could identify sub-populations of patients among high-risk Caucasian individuals (HBV/HCV-positive), which had differential predispositions for HCC development. The *ABCB1* rs1128503 and *ERCC1* rs3212986 variants displayed different effects, based on the viral status of the patient (HBV- or HCV-positive serology). This result was consistent with the molecular and clinical-pathological differences between HBV- and HCV-related hepatocarcinogenesis\[[@B18]\]. Two polymorphisms (*ERCC1* rs3212986, and *CYP17A1* rs743572) could also predict HCC risk among the healthy Caucasian population. A CART analysis provided evidence of gene-gene interactions between *ERCC1* rs3212986, *CYP17A1* rs743572, *GST-P1* rs1138272, and the previously described *UGT1A7*\*3 marker. These interactions defined subgroups of patients with genetic combinations that could further increase the risk of HCC.

The *ERCC1* rs3212986 (8092G\>T) polymorphism was demonstrated to be a strong protective factor against liver cancer development in both high-risk (HCV/HBV-positive) and healthy individuals. Furthermore, in an analysis of subgroups with different viral statuses, a particularly significant effect was detected in the HCV-positive subgroup.

ERCC1 is one of several key rate-limiting enzymes in the nucleotide excision repair (NER) pathway. The NER mechanism of the DNA repair system maintains genomic integrity by removing inter-strand DNA crosslinks, and thus, it influences the cell's sensitivity to DNA-adducting carcinogens\[[@B19]\]. A NER-related reduction in DNA repair capacity has been associated with some types of tumors (*i.e*., lung, head and neck, prostate, glioma, ovarian cancers). Accordingly, *ERCC1* gene variants were shown to influence susceptibility to cancer\[[@B20],[@B21]\]. However, few studies have investigated the implication of the NER biological pathway and *ERCC1* polymorphisms, including rs3212986\[[@B20],[@B21]\], in hepatocarcinogenesis, and no data are available in Caucasian populations. The *ERCC1* rs3212986 variant, located in the 3' untranslated region (3'UTR) of the gene, is thought to increase transcript stability, although further biochemical studies are required to clarify the effect of this polymorphism on gene transcription and protein translation\[[@B22],[@B23]\]. Based on our data, we inferred that the rs3212986 variant allele was associated with elevated ERCC1 expression and/or activity, which could lead to enhanced protection against the accumulation of mutagenic DNA lesions, and consequently, against hepatocarcinogenesis. However, we could not exclude that this marker might also be closely linked to other functionally relevant genetic variants\[[@B21]\] that might alter ERCC activity and/or HCC onset.

The *XRCC3* rs1799794 (4541A\>G) marker was associated with elevated HCC susceptibility in a high-risk (HCV/HBV-positive) population. XRCC3 is another DNA repair protein that participates in the DNA double-strand break/recombination repair machinery. XRCC3 was shown to be involved in the pathogenesis of many cancers, including HCC\[[@B24],[@B25]\]. Reduced XRCC3 activity was associated with significantly elevated levels of bulky DNA adducts\[[@B26]\]. Furthermore, epidemiological evidence, derived mainly from studies in an Asian population, have shown that XRCC3 contributed to the repair of DNA damage induced by environmental toxins, such as aflatoxin B1, and that this effect depended on viral status and ethnicity\[[@B25],[@B27]\]. The *XRCC3* rs1799794 variant, located in a regulatory region in the 5'UTR of the gene, was predicted to have a potential effect on protein expression levels\[[@B28]\]. The results of the present study suggested that this polymorphism could reduce the ability to repair DNA adducts, which would contribute to the accumulation of mutagenic lesions, and thus, increase the risk of HCC onset. However, the exact molecular mechanism of the rs1799794 variant is currently unknown, and we could not exclude a linkage with another functional marker\[[@B29]\].

The *GST-P1* rs1138272 (341C\>T) polymorphism was found to have a protective effect on liver cancer development in a high-risk HCV/HBV-positive population. GST-P1 belongs to the GST multigene family. It is a phase II enzyme involved in the inactivation of electrophilic xenobiotics by conjugation with glutathione\[[@B30]\], which facilitates the excretion of molecules that are potentially toxic to the liver\[[@B31]\]. This enzyme also contributes to protecting liver cells from damage related to reactive oxygen species generated, for instance, by chronic alcohol and tobacco abuse\[[@B32]\]. Several studies have clearly demonstrated that silencing GST-P1 expression by promoter methylation was positively correlated with the incidence of HCC\[[@B31]\] and with virus-related hepatocarcinogenesis\[[@B33]\]. In contrast, in meta-analyses, *GST-P1* genetic polymorphisms (*i.e*., Ile105Val, rs1695) were not associated with HCC risk\[[@B34],[@B35]\] although the few data available were insufficient for drawing any definite conclusions. The less investigated *GST-P1* rs1138272 polymorphism is a missense variant (Val114Ala) that lies in the electron binding, active domain of the protein. This variant was reported to affect substrate specificity by altering its ability to distinguish between planar and non-planar substrates\[[@B36],[@B37]\]. Our results suggested that this functional change in GST-P1 activity may result in a lower risk of HCC development; further clinical experimental studies are required to clarify the role of the rs1138272 polymorphism in the response of GST-P1 to environmental xenobiotics and oxidative stress, particularly in a virus-infected liver.

The *CYP17A1* rs743572 (-34T\>C) polymorphism was found to be a strong protective factor against HCC development in both the high-risk HCV/HBV-positive group and healthy individuals. CYP17A1 is an enzyme that plays a critical role in the biosynthesis of steroid hormones by catalyzing both 17a-hydroxylase and 17, 20-lyase activities\[[@B38]\]. Some data derived from animal models and human epidemiologic studies have demonstrated that estrogens play an essential role in hepatocarcinogenesis; however, the exact mechanism underlying the effect of estrogen levels on HCC development is currently controversial\[[@B39]\]. It was initially suggested that the *CYP17A1* rs743572 variant, located in the 5'UTR of the gene, served as a new Sp1-type (CCACC box) binding site, which provided an additional promoter, and thus, it could increase estrogen biosynthesis\[[@B40]\]. However, subsequent studies could not replicate the phenotypic impact of this variant on CYP17A1 mRNA expression or estrogen levels\[[@B41]\]. Moreover, the involvement of the rs743572 marker on HCC development was not well defined\[[@B42],[@B43]\]. From the present data, it could be speculated that the rs743572 variant might contribute to changing CYP17A1 activity, and its dependent steroid levels, to provide a protective effect against liver cancer development. Estrogen is known to participate in various biological functions. For example, an increase in sex hormone levels was suggested to suppress the inflammatory processes mediated by pro-inflammatory cytokines\[[@B44],[@B45]\]. Additional work will be required to clarify the functional significance of the rs743572 marker and the molecular mechanism of CYP17A1 in hepatocellular carcinogenesis.

Finally, A*BCB1* rs1128503 (1236C\>T) was associated with elevated HCC susceptibility in a high-risk (HCV/HBV-positive) population. Furthermore, an analysis of subgroups with different viral statuses showed that a particularly significant effect was detected in the HBV-positive subgroup. The *ABCB1* gene encodes MDR-1, also known as P-glycoprotein (P-gp). MDR-1 belongs to the ATP-binding cassette (ABC) transporter superfamily\[[@B46],[@B47]\]. This membrane efflux pump is widely expressed in various organs, including the liver, and it is physiologically involved in the protection of normal tissue from environmental and endogenous toxins\[[@B46]-[@B48]\]. MDR1 is implicated in hepatic clearance of oxidative and other genotoxic products generated by chronic inflammation induced by HCC risk factors. Thus, it contributes to preventing the initiation of hepatocarcinogenesis\[[@B49],[@B50]\]. Many studies have described MDR1 over-expression in various tumor tissues, including liver cancer\[[@B51]\]; thus, this membrane carrier and its functional genetic variants are good candidates for influencing liver susceptibility to HCC. *ABCB1* rs1128503 is a synonymous variant (Gly412Gly) of a residue located in the cytoplasmic domain of the transporter. It is reported to affect mRNA stability\[[@B52]\], but the exact phenotypic impact of this variant on protein expression/activity remains to be defined\[[@B53],[@B54]\]. Several studies, performed in Asian populations, have investigated associations between *ABCB1* polymorphisms (including rs1128503) and the risk of developing HCC. A recent meta-analysis\[[@B55]\] showed that polymorphic alleles of the *ABCB1* gene significantly increased HCC risk. In analyses of subgroups with different types of variations, both synonymous and non-synonymous polymorphisms were associated with elevated liver cancer susceptibility. In particular, synonymous variants (*i.e*., rs1128503) were suggested to be correlated with changes in transcriptional and translational processes. In addition, genetic markers located in the cytoplasmic domain of the transporter, like rs1128503, were shown to have the greatest predictive power for HCC risk. These data, although obtained in Asian cohorts, were consistent with the result of the present study, which provided the first evidence of a role of the *ABCB1* rs1128503 marker in HCC risk in a Caucasian population.

Due to the multifactorial nature of hepatocarcinogenesis, an exploratory CART analysis was applied to investigate interactions between the genetic factors identified as predictors of liver cancer susceptibility in the high-risk population (HBV/HCV-infected group). The polymorphism in the gene of the DNA repair system (*i.e., ERCC1* rs3212986) was demonstrated to significantly interact with variants of genes that encoded phase I (*CYP17A1* rs74357) and II (*GST-P1* rs1138272, *UGT1A7*\*3) metabolic enzymes; these interactions were important in defining individual HCC risk. The CART analysis generated a distinctive clustering of subjects, according to different probabilities of developing liver cancer. These data pointed out that previously acknowledged predictive markers, such as the *UGT1A\*3* polymorphism\[[@B14]\], should be considered in association with novel identified genetic variants for properly defining the complex trait of HCC susceptibility. In particular, *ERCC1* rs3212986 was shown to be the most relevant polymorphism for HCC risk stratification, because it appeared twice in the generated tree. This marker significantly interacted with three additional genetic variants (*CYP17A1* rs74357, *GST-P1* rs1138272, and *UGT1A7*\*3) in defining individual susceptibility. The analysis of gene-gene interactions and the network shape uncovered specific genetic-context effects that could not be detected in evaluations of single markers. These findings highlighted the importance of combining genetic markers to obtain a better representation of the biological cooperation among multiple pathways in hepatocarcinogenesis.

The present study had some limitations. First, our case-cohort comprised a highly specific group of patients with HCC (patients that received OLT). These patients had definite clinical features that could limit the generalizability of the present findings. The validity of the present results was also limited to Caucasian individuals; the results remain to be verified in other populations, like Asians or Africans. Second, our work did not evaluate other confounding etiological factors, such as smoking and alcohol intake. However, the use of a control group matched to HCC cases for HBV/HCV viral status permitted us to control for this crucial confounding variable. Third, the exact functional and phenotypic properties of some of the genetic markers that we identified as predictors of HCC risk have not been well established. Moreover, we could not exclude any linkages with other functionally relevant genetic variants. Finally, considering the retrospective and exploratory nature of our case-control analysis, the results obtained should be interpreted with caution. Our findings will require independent validation in future prospective, large-scale epidemiological investigations that are performed in well-defined, homogeneous populations.

The validation of the present findings could have important clinical implications for improving HCC management. The novel identified genetic markers and their gene-gene interactions, in combination with other well-known serum biomarkers (*e.g*., alphafetoprotein) and diagnostic imaging (*e.g*., ultrasonography)\[[@B9]\], could contribute to improving the HCC risk stratification algorithms and surveillance programs, particularly for patients at risk. Those improvements might facilitate early cancer detection and might lead to potentially curative therapies. Furthermore, an enhanced understanding of the genetic factors associated with the evolution of HCV infection could be essential for the optimized use of the recently developed, but highly expensive, anti-HCV DAAs\[[@B12],[@B13]\]. Thus, improved screening could assist the health care system in containing costs and ensuring the most clinically appropriate treatments.

The present study identified five variants in genes that encode DNA repair system proteins (*i.e*., ERCC1, XRCC3), phase I (*i.e*., CYP17A1) and II (*i.e*., GST-P1) enzymes, and a membrane transporter (*i.e*., MDR-1). Our data suggested that these genes might play a role in predicting HCC susceptibility in a high-risk (HBV-HCV infected) population and in a healthy Caucasian population. The CART analysis pointed out the potential value of studying of gene-gene interactions for the stratification of individuals at different risks of developing HCC. Although validation is required, these preliminary results might have important clinical implications in the management of HCC prevention and patient care.
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Background
----------

Hepatocellular carcinoma (HCC) represents a global health problem, due to its high incidence and mortality rates. Although the etiologies of this neoplasia are well-defined, the majority of patients are diagnosed at advanced-stage disease, which excludes them from receiving a potentially curative therapy. Hence, they urgently need the definition of new biomarkers of HCC susceptibility that can permit early cancer detection, particularly for individuals in a high-risk population \[hepatitis B (HBV)/hepatitis C (HCV)-positive\]. Moreover, in developed countries (*i.e*., United States and Europe), HCV-related HCC can account for most liver cancers; therefore, increasing our knowledge of the genetic contribution to the clinical course of viral infections could be essential in optimizing the use of the newly developed, but highly expensive, direct acting antiviral treatments.

Research frontiers
------------------

Accumulating data derived from candidate-gene investigations and genome-wide association studies have highlighted the possible role of genetic variants as significant predictors of HCC susceptibility and as determinants of the clinical course of HBV or HCV infections. However, the high heterogeneity among published works has prevented drawing definite conclusions. Furthermore, the majority of case-control investigations were performed in Asian populations; thus, replication studies with different ethnicities are warranted. Consequently, there is a critical need to intensify research efforts in identifying effective molecular biomarkers predictive of individual HCC risk in a homogeneous, well-defined cohort study, with particular attention to the (currently) poorly investigated Caucasian population.

Innovations and breakthroughs
-----------------------------

This work uncovered five markers in genes that encode key proteins involved in pathways underlying hepatocarcinogenesis (*ERCC1*-rs3212986, *GSTP1-*rs1138272, *CYP17A1*-rs743572, *XRCC3*- rs1799794, and *ABCB1*-rs112850). These markers were predictive of individual HCC susceptibility in a high-risk Caucasian population (HBV/HCV-positive). Two variants also exhibited serology-specific effects when a subgroup analysis was performed in patients stratified according to HBV or HCV positive serology. That analysis showed that *ABCB1* rs1128503 specifically affected the HBV-positive subgroup and *ERCC1* rs3212986 specifically affected the HCV-positive subgroup. Among the five markers identified, *ERCC1* rs3212986 and *CYP17A1* rs743572 retained predictive value for HCC risk among healthy individuals. In addition, they found gene-gene interactions between *ERCC1* rs3212986, *CYP17A1* rs743572, *GST-P1* rs1138272, and the previously described *UGT1A7*\*3 marker, which were included in the definition of the complex trait of HCC susceptibility.

Applications
------------

The definition of genetic traits that confer susceptibility to liver carcinogenesis is of potential clinical interest. This information can facilitate improvements in preventive, diagnostic, and therapeutic strategies for HCC management. If validated, these markers and their interactions should be considered for improving HCC risk stratification algorithms and surveillance programs. Their inclusion in screening could facilitate early cancer detection and might lead to potentially curative therapies. For patients with HCV infections, the biomarkers we discovered could also contribute to optimizing the use of recently developed, but highly expensive, anti-viral therapies. These findings address a great challenge in HCC management and might help enhance care for patients with HCC.

Terminology
-----------

Polymorphism: a variation in the DNA sequence that occurs in a population at a frequency of 1% or higher; CART: classification and regression tree analysis; this is a statistical method, based on recursive partitioning, that is applied to elucidate potential high-order gene-gene and gene-environmental relationships among discriminating factors that contribute to a specific end-point; ERCC1: a key rate-limiting enzyme that acts in the nucleotide excision repair pathway. This pathway represents a DNA repair mechanism designed to maintain genomic integrity by removing inter-strand DNA crosslinks; XRCC3: a DNA repair protein that participates in DNA double-strand break/recombination repair machinery; GST-P1: a phase II enzyme involved in the inactivation of electrophilic xenobiotics; it acts by conjugating with glutathione, which facilitates excretion of xenobiotics from the body; CYP17A1: an enzyme that plays a critical role in the in the biosynthesis of steroid hormones; MDR-1 (encoded by *ABCB1*): A widely expressed membrane efflux pump, physiologically involved in the protection of normal tissue from environmental and endogenous toxins.

Peer-review
-----------

The aim of this study was to find novel genetic markers that could contribute in predicting HCC susceptibility in Caucasians. The authors identified five genetic markers in key pathways linked to hepatocarcinogenesis (ERCC1-rs3212986, GSTP1-rs1138272, CYP17A1-rs743572, XRCC3- rs1799794, ABCB1-rs112850) that could predict the individual HCC susceptibility, especially in high-risk (HBV/HCV-infected) Caucasians population. The article provides the novel informations that could contribute to improving HCC surveillance, allowing early cancer diagnosis and possible curative therapy.
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